Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

4.2K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
4.2K
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

3.5K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.5K
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

3.5K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
3.5K
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

536
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
536
Chronic Obstructive Pulmonary Disease01:22

Chronic Obstructive Pulmonary Disease

2.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.2K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

1.7K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.7K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Association of bronchoalveolar lavage cellular analysis and radiological findings in fibrotic interstitial lung diseases.

BMJ open respiratory research·2026
Same author

Correction: Progressive pulmonary fibrosis.

European radiology·2026
Same author

Case Report: Decoding genetic risks of vascular parkinsonism: a case series.

Frontiers in genetics·2025
Same author

APOE genetic variability in an Egyptian cohort of PD.

Frontiers in neuroscience·2025
Same author

Evaluation of the safety of short-term follow-up CT for the management of consolidation in lung cancer screening.

European radiology·2025
Same author

Deep-learning CT imaging algorithm to detect usual interstitial pneumonia pattern in patients with systemic sclerosis-associated interstitial lung disease: association with disease progression and survival.

Rheumatology (Oxford, England)·2024

関連する実験動画

Updated: Jan 8, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

860

進行性肺線維症

Ramey Bajwa1, Drew Lancaster2, Sujal R Desai3,4

  • 1Department of Interstitial Lung Disease, Royal Brompton Hospital, London, UK. rameybajwa@gmail.com.

European radiology
|December 19, 2025
PubMed
まとめ
この要約は機械生成です。

進行性肺線維症（PPF）は特発性肺線維症（IPF）に似ており、死亡率を増加させます。CTスキャンで放射線学的進行を特定することは、タイムリーな抗線維化治療と肺機能低下の遅延に不可欠です。

キーワード:
抗線維化薬コンピューター断層撮影ニンテダニブ進行性肺線維症線維症の放射線学的進行

さらに関連する動画

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

807
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

1.5K

関連する実験動画

Last Updated: Jan 8, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

860
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

807
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

1.5K

科学分野:

  • 肺学
  • 放射線学
  • 医用画像処理

背景:

  • 非特発性肺線維症（IPF）の一部のケースでは、進行性肺線維症（PPF）の軌跡が示されます。
  • PPFは、患者の死亡率の増加と関連しており、臨床的にはIPFに似ています。
  • PPFの特定は、患者管理と予後にとって重要です。

研究 の 目的:

  • PPFを特定するための放射線学的進行基準を定義すること。
  • PPF患者の管理における放射線科医の役割を強調すること。
  • 抗線維化療法のための早期検出の重要性を強調すること。

主な方法:

  • シリアル高解像度コンピューター断層撮影（CT）スキャンの分析。
  • 経時的な線維症の範囲と重症度の変化の評価。
  • 非IPF症例における進行の放射線学的評価。

主要な成果:

  • PPFにおける放射線学的進行は、線維症の全体的な範囲の増大によって特徴付けられます。
  • 進行は、線維症の範囲全体は変化しないものの、線維症の重症度が増すことによっても現れる可能性があります。
  • 正確な放射線学的特定は、タイムリーな介入を可能にします。

結論:

  • 放射線科医は、CT評価によるPPFの診断において極めて重要です。
  • 放射線学的進行を特定することで、抗線維化薬の開始が可能になります。
  • 早期の抗線維化治療は、PPFにおける肺機能低下を大幅に軽減することができます。